Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.67 |
| ▸ | METAP2 | P50579 | 3/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 6/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924097 | 0.80 | METAP2 (1.00) | METAP1METAP2AURKA | |
| SCHEMBL680854 | 0.77 | METAP2 (0.65) | METAP1METAP2NPY5RAURKAPTGDR2 | |
| SCHEMBL6385063 | 0.77 | METAP2 (0.60) | METAP1METAP2NPY5RWNT1 | |
| SCHEMBL9990569 | 0.77 | METAP1 (0.63) | METAP1METAP2NPY5RFGFR1FLT1 | |
| SCHEMBL7035590 | 0.76 | METAP1 (0.72) | METAP1METAP2NPY5RFGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL4456676 | 0.76 | METAP2 (0.63) | METAP1METAP2NPY5RAURKAPTGDR2 | |
| SCHEMBL27787407 | 0.76 | METAP1 (0.66) | METAP1METAP2FGFR1FLT1PDE5A | |
| SCHEMBL369485 | 0.75 | METAP2 (0.61) | METAP1METAP2NPY5R | |
| SCHEMBL2045300 | 0.74 | METAP1 (0.60) | METAP1METAP2NPY5RFGFR1FLT1 | |
| SCHEMBL13137746 | 0.73 | METAP2 (0.56) | METAP1METAP2NPY5RFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449470-B2 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2008-11-11 | — | — | US | disclosed |
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | UNIVERSITEIT LEIDEN (NL) | 2007-02-08 | — | — | US | disclosed |
| EP-1667985-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | Universiteit Leiden (NL) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005033084-A1 | SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS | UNIVERSITEIT LEIDEN (NL) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032510-A1 | Substituted pyrimidines as ligands of adenosine receptors | ADORA2A, ADORA3, ADORA1 | METAP1 2160/4885METAP2 1800/4885NPY5R 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.